Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2025), N Engl J Med, 392, 777 - 787
Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease.
Zhu D. et al, (2025), Nephrol Dial Transplant, 40, i70 - i79
Mortality risks in different subtypes of masked hypertension in the Spanish ambulatory blood pressure monitoring registry.
de la Sierra A. et al, (2024), J Hypertens
Resistant Hypertension and Mortality: An Observational Cohort Study.
de la Sierra A. et al, (2024), Hypertension, 81, 2350 - 2356
Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial.
O'Hara DV. et al, (2024), BMJ Open, 14
A global view on kidney care.
Staplin N., (2024), Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 39, ii1 - ii2
Design, recruitment and baseline characteristics of the LENS trial.
LENS Collaborative Group None., (2024), Diabet Med, 41
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression Trials.
Fletcher RA. et al, (2024), Clin J Am Soc Nephrol, 19, 1180 - 1182
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.
Apperloo EM. et al, (2024), Lancet Diabetes Endocrinol, 12, 545 - 557
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) for hospitalised patients with COVID-19: prospective meta-analysis of randomised trials
LANDRAY M. et al, (2024), The Lancet Diabetes and Endocrinology
A blunted nocturnal blood pressure decline is associated with all-cause and cardiovascular mortality.
de la Sierra A. et al, (2024), J Hypertens, 42, 1197 - 1202
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129
Office measurement vs. ambulatory blood pressure monitoring: associations with mortality in patients with or without diabetes.
Böhm M. et al, (2024), Eur Heart J
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Patel SM. et al, (2024), Circulation, 149, 1789 - 1801
Artificial Intelligence-Derived Risk Prediction: A Novel Risk Calculator Using Office and Ambulatory Blood Pressure.
Guimarães P. et al, (2024), Hypertension